Studies in neurons and animal models have demonstrated that maintaining normal APC/C-Cdh1 activity may mitigate Aβ-induced neurotoxic effects, suggesting potential therapeutic targets for AD [53]. This evidence concerns the gene CDH1 and Alzheimer disease.